FierceBiotech Mar 10, 2026 Republican senator slams FDA rare disease rebuffs, pledges to investigate recent actions: Bloomberg
FierceBiotech Mar 10, 2026 FDA reconsidering Capricor’s snubbed DMD cell therapy after 'lifting' rejection
FierceBiotech Mar 9, 2026 Tenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater China
FierceBiotech Mar 9, 2026 Roche's oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits
FierceBiotech Mar 9, 2026 Italy's Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision
FierceBiotech Mar 9, 2026 Why early developability assessment is a strategic necessity in modern antibody discovery
FierceBiotech Mar 6, 2026 FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap
FierceBiotech Mar 6, 2026 Beam rejigs deal to retain base editing technology amid partner's dissolution
FierceBiotech Mar 6, 2026 Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda